<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946231</url>
  </required_header>
  <id_info>
    <org_study_id>BSTE-0108</org_study_id>
    <nct_id>NCT00946231</nct_id>
  </id_info>
  <brief_title>Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home</brief_title>
  <acronym>HABIT</acronym>
  <official_title>HF Assessment With BNP In The Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosite</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inverness Medical Innovations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosite</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HABIT clinical study is being performed to determine the benefit and optimal frequency&#xD;
      for at home testing of B-type natriuretic peptide (BNP) for heart failure patients following&#xD;
      hospitalization from decompensation. Subjects will be enrolled following hospitalization for&#xD;
      decompensated heart failure. Enrolled subjects will be trained on the use of the Triage Touch&#xD;
      meter for fingerstick BNP assessment; these subjects will then test their BNP levels daily&#xD;
      using the Triage Touch product for approximately 60 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, single-arm double-blinded prospective clinical study to determine the&#xD;
      optimal frequency of home B-type natriuretic peptide (BNP) testing and the changes in BNP&#xD;
      concentrations that correlate with clinical heart failure (HF) decompensation and related&#xD;
      adverse clinical outcomes in at-risk HF patients. Approximately 200 subjects will be&#xD;
      enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To use the Triage touch to determine the optimal frequency of home BNP testing and the changes in BNP concentrations that correlate with clinical HF decompensations and related adverse events in at-risk HF patients.</measure>
    <time_frame>Day 5, Day 30 and Day 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the feasibility of frequent home BNP self-testing with the Triage touch in the study population.</measure>
    <time_frame>Day 5, Day 30 and Day 60</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">187</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
    <description>Subjects admitted to the hospital with decompensated heart failure.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects admitted to the hospital with decompensated Heart Failure. Subjects may be&#xD;
        enrolled while still in the hospital or within 3 days post-discharge through a heart&#xD;
        failure clinic or other type of outpatient clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years of age or older);&#xD;
&#xD;
          -  Admitted to the hospital or observation unit with a diagnosis of decompensated HF for&#xD;
             which treatment will be administered;&#xD;
&#xD;
          -  Blood BNP level measurement &gt; 400 pg/mL documented during admission; If NT-proBNP is&#xD;
             used routinely in the laboratory at a clinical site rather than BNP, then blood&#xD;
             NT-proBNP level measurement &gt; 1,600 pg/mL documented during admission.&#xD;
&#xD;
          -  Successfully trained on how to perform a fingerstick and to use the Triage touch.&#xD;
&#xD;
          -  Either the subject or their care provider is fluent in reading and writing English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to provide written informed consent;&#xD;
&#xD;
          -  Acute coronary syndrome (ACS) that is concomitant with the diagnosis of decompensated&#xD;
             HF and for which treatment will be provided.&#xD;
&#xD;
        A history of ACS is not reason for exclusion if it is not concomitant with the present&#xD;
        decompensated HF for which admission is being made. Small elevations in cardiac troponin&#xD;
        that are considered by the treating physician to be associated with myocardial injury due&#xD;
        to the acute decompensated HF and not due to a concomitant ACS or myocardial infarction are&#xD;
        not a basis for exclusion.&#xD;
&#xD;
          -  Previous cardiac transplantation - or cardiac transplantation anticipated within 3&#xD;
             months;&#xD;
&#xD;
          -  Current or planned use of a left ventricular assist device (LVAD), use of outpatient&#xD;
             intravenous inotropic HF therapy, major surgical procedure or percutaneous coronary&#xD;
             intervention within 3 months;&#xD;
&#xD;
          -  Life expectancy less than 3 months due to causes other than HF or cardiovascular&#xD;
             disease (e.g., cancer);&#xD;
&#xD;
          -  End stage renal disease;&#xD;
&#xD;
          -  Prisoner or other institutionalized or vulnerable individual;&#xD;
&#xD;
          -  Residence in regions where either transmission of Triage Touch data or a home visit on&#xD;
             day 5 is not possible.&#xD;
&#xD;
          -  Dementia, tremors or other impediments to performing daily home BNP testing via&#xD;
             fingerstick.&#xD;
&#xD;
          -  Deemed by the Investigator not to be likely to comply with study-mandated procedures&#xD;
             or instructions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S Maisel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Affairs San Diego Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Care Clinical Research Corp DBA Beaver Medical Center</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic Torrey Pines</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda VA Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Internal Medical Group</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josephs Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cardiology Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cardiac Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA- UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>August 30, 2012</last_update_submitted>
  <last_update_submitted_qc>August 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <name_title>Clinical Study Manager</name_title>
    <organization>Biosite Incorporated</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>BNP</keyword>
  <keyword>B-type natriuretic peptide</keyword>
  <keyword>home testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

